{"filing":{"accession_number":"0001493152-26-040329","cik":"0001054102","ticker":"IDXG","company_name":"INTERPACE BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315226040329/form8-k.htm"},"events":[{"id":29929,"run_id":27427,"accession_number":"0001493152-26-040329","anchor_item_number":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses a reverse stock split (1-for-5 ratio) approved by stockholders on August 20, 2026 and effective August 27, 2026, implemented via amendment to the Certificate of Incorporation (Item 5.03). While a reverse split is a capital structure change, it is fundamentally a governance/corporate action matter—an amendment to the articles of incorporation—rather than a financial event like debt issuance or impairment. The split is material because it affects all shareholders' ownership structure and is intended to support a Nasdaq uplisting, which would materially affect the company's market access and investor base.","company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":32372,"accession_number":"0001493152-26-040329","item_number":null,"item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a reverse stock split (1-for-5 ratio) approved by stockholders on August 20, 2026 and effective August 27, 2026, implemented via amendment to the Certificate of Incorporation (Item 5.03). While a reverse split is a capital structure change, it is fundamentally a governance/corporate action matter—an amendment to the articles of incorporation—rather than a financial event like debt issuance or impairment. The split is material because it affects all shareholders' ownership structure and is intended to support a Nasdaq uplisting, which would materially affect the company's market access and investor base.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:31:55.676328+00:00","company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","filing_date":"2026-08-27"}]}